Rocket Pharmaceuticals, Inc. (FRA:9IP1)

Market Cap	319.19M
Revenue (ttm)	n/a
Net Income (ttm)	-205.33M
Shares Out	n/a
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	395
Open	2.754
Previous Close	2.498
Day's Range	2.754 - 2.754
52-Week Range	1.778 - 13.390
Beta	n/a
RSI	54.49
Earnings Date	Feb 26, 2026

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 299
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9IP1

Financial Performance

Financial numbers in USD